FRAMINGHAM, MA / ACCESSWIRE / January 14, 2021 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCARTâ„¢, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at NobleCon17 - Noble Capital Markets' Seventeenth Annual Investor Conference on Tuesday, January 19, 2021 at 9:45 AM ET.
FRAMINGHAM, MA / ACCESSWIRE / January 5, 2021 / Xenetic Biosciences, Inc.
FRAMINGHAM, MA / ACCESSWIRE / December 14, 2020 / Xenetic Biosciences, Inc.